These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND NTRK1, ENSG00000198400, 4914, P04629, TRK1, MTC, DKFZp781I14186, p140-TrkA, TRKA, TRK AND Treatment
869 results:

  • 1. [Not Available].
    Ciappuccini R; Nascimento C; Edet-Sanson A; Bardet S
    Bull Cancer; 2024 Oct; 111(10S1):10S64-10S72. PubMed ID: 39505438
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin.
    Wang B; Huang J; Chen L
    Front Endocrinol (Lausanne); 2024; 15():1418657. PubMed ID: 39449744
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Unveiling new chapters in medullary thyroid carcinoma therapy: advances in molecular genetics and targeted treatment strategies.
    Huai JX; Wang F; Zhang WH; Lou Y; Wang GX; Huang LJ; Sun J; Zhou XQ
    Front Endocrinol (Lausanne); 2024; 15():1484815. PubMed ID: 39439561
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Photosensitizing metal-organic framework nanoparticles combined with tumor-sensitization strategies can enhance the phototherapeutic effect upon medullary thyroid carcinoma.
    Feng Y; Jiang Q; Ma X; Sun H; Chai Y; Li X; Wang Z; Feng F
    Biochim Biophys Acta Gen Subj; 2024 Dec; 1868(12):130725. PubMed ID: 39433228
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Unusual Presentation of Metastatic Medullary Thyroid Cancer Involving Bone Marrow, Kidneys, and Adrenal Gland: A Literature Review Based on a Case Report.
    Ebrahimi P; Payab M; Shariati A; Alipour N; Nozheh A; Tavangar SM; Taheri H; Ebrahimpur M
    Cancer Rep (Hoboken); 2024 Oct; 7(10):e70022. PubMed ID: 39410877
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. ERK signaling promotes resistance to trk kinase inhibition in Ntrk fusion-driven glioma mouse models.
    Schmid S; Russell ZR; Yamashita AS; West ME; Parrish AG; Walker J; Rudoy D; Yan JZ; Quist DC; Gessesse BN; Alvinez N; Hill KD; Anderson LW; Cimino PJ; Kumasaka DK; Parchment RE; Holland EC; Szulzewsky F
    Cell Rep; 2024 Oct; 43(10):114829. PubMed ID: 39365700
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
    Zhang Y; Zheng WH; Zhou SH; Gu JL; Yu Q; Zhu YZ; Yan YJ; Zhu Z; Shang JB
    Cell Commun Signal; 2024 Sep; 22(1):460. PubMed ID: 39342195
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Long-Term tumor Stability After First-Line treatment With Larotrectinib in an Infant With Ntrk2 Fusion-Positive High-Grade Glioma.
    Simoneau J; Robertson P; Muraszko K; Maher CO; Garton H; Calvert R; Koschmann C; Upadhyaya SA; Mody R; Brown N; Kumar-Sinha C; Parmar H; Camelo-Piragua S; Franson AT
    J Natl Compr Canc Netw; 2024 Sep; 22(7):. PubMed ID: 39236755
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Simultaneous occurrence of papillary thyroid carcinoma, medullary thyroid carcinoma, and lymphoma: A case report.
    Hao Z; Cui H; Li Y; Wu W; Wang Y; Dan H; Lou L; Wang H; Zhao P
    Medicine (Baltimore); 2024 Aug; 103(33):e39363. PubMed ID: 39151514
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib.
    Gambale C; Prete A; Romei C; Celi A; Elisei R; Matrone A
    Eur Thyroid J; 2024 Oct; 13(5):. PubMed ID: 39136571
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A practical nomogram for preoperatively predicting lateral cervical lymph node metastasis in medullary thyroid carcinoma: a dual-center retrospective study.
    Zhu J; Guo T; Guo S; Chang L; Zhao J; Wang X; Wei X
    Front Endocrinol (Lausanne); 2024; 15():1349853. PubMed ID: 39129917
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Durability of Response With Selpercatinib in Patients With
    Wirth LJ; Brose MS; Subbiah V; Worden F; Solomon B; Robinson B; Hadoux J; Tomasini P; Weiler D; Deschler-Baier B; Tan DSW; Maeda P; Lin Y; Singh R; Bayt T; Drilon A; Cassier PA
    J Clin Oncol; 2024 Sep; 42(27):3187-3195. PubMed ID: 39094065
    [No Abstract]    [Full Text] [Related]  

  • 13. Biomarker identification of medullary thyroid carcinoma from gene expression profiles considering without-treatment and with-treatment studies-A bioinformatics approach.
    Loganathan T; George Priya Doss C
    Adv Protein Chem Struct Biol; 2024; 142():367-396. PubMed ID: 39059991
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Atypical cellular responses mediated by intracellular constitutive active trkB (Ntrk2) kinase domains and a solely intracellular Ntrk2-fusion oncogene.
    Gupta R; Dittmeier M; Wohlleben G; Nickl V; Bischler T; Luzak V; Wegat V; Doll D; Sodmann A; Bady E; Langlhofer G; Wachter B; Havlicek S; Gupta J; Horn E; Lüningschrör P; Villmann C; Polat B; Wischhusen J; Monoranu CM; Kuper J; Blum R
    Cancer Gene Ther; 2024 Sep; 31(9):1357-1379. PubMed ID: 39039193
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).
    Leboulleux S; Kapiteijn E; Litière S; Schöffski P; Godbert Y; Rodien P; Jarzab B; Salvatore D; Zanetta S; Capdevila J; Bastholt L; De La Fouchardiere C; Lalami Y; Bardet S; Cornélis F; Dedecjus M; Links T; Sents W; Schlumberger M; Locati DL; Newbold K
    Front Endocrinol (Lausanne); 2024; 15():1403687. PubMed ID: 39015176
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Ntrk-fused central nervous system tumours: clinicopathological and genetic insights and response to trk inhibitors.
    Kim EE; Park CK; Kim SK; Phi JH; Paek SH; Choi JY; Kang HJ; Lee JH; Won JK; Yun H; Park SH
    Acta Neuropathol Commun; 2024 Jul; 12(1):118. PubMed ID: 39014476
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The Multi-Institutional Medullary Thyroid Cancer Collaborative Registry: Can a Rare tumor Registry Accurately Represent the Real-World Patient Population?
    Szabo Yamashita T; Williams-Perez SM; Ehsan S; Mulder M; Kronenfeld D; Huang CY; Zhao H; Merriman K; Peterson SK; Hu MI; Zafereo M; Sosa JA; Grubbs EG
    Thyroid; 2024 Sep; 34(9):1117-1125. PubMed ID: 38984944
    [No Abstract]    [Full Text] [Related]  

  • 18. Critically evaluated key points on hereditary medullary thyroid carcinoma.
    Zhang D; Liang N; Sun H; Frattini F; Sui C; Yang M; Wang H; Dionigi G
    Front Endocrinol (Lausanne); 2024; 15():1412942. PubMed ID: 38919477
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The impact of preoperative calcitonin screening on the prognosis of patients with medullary thyroid cancer: a retrospective multicenter cohort study.
    Hou Y; Yang Y; Chen G; Long J; He Y; Xiong D; Pang Y; Li Q; Dong G; Qiao S; Chen W; Li X; Zhang J; Xu T; Chen X; Lai F; Guan H; Lin B; Liu Y
    Endocrine; 2024 Aug; 85(2):827-836. PubMed ID: 38834859
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer.
    Pitoia F; Trimboli P; Abelleira E
    Endocrine; 2024 Oct; 86(1):109-113. PubMed ID: 38801596
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 44.